YK-11 SARM claims vs. what the science actually shows

What did @redskull_coaching actually say?

Honestly, this is a tough one to fact-check. The transcript provided for this video is largely incoherent, a garbled machine-translation artifact that reads like an AI trained on bureaucratic documents, not a French fitness coach talking about YK-11. What we can work with is the caption, which is actually more informative than the transcript.

The caption states clearly that YK-11 is "very interesting on paper" but does not deliver the results that the hype around it promises. That is a measured, skeptical take from someone who apparently tried the compound personally. The creator is essentially telling their 61,000 viewers: don't believe the buzz on this one. That is a more responsible message than most YK-11 content on TikTok, which tends to frame it as a legal, side-effect-free shortcut to steroid-level gains.

We cannot quote the transcript directly because it is not usable. The analysis below focuses on the claims implied by the caption and the broader YK-11 discourse this video is clearly participating in.

Does the science back this up?

Yes, largely. The claim that YK-11 underdelivers relative to its hype is well-supported by the absence of human clinical data. YK-11 has essentially no peer-reviewed human trials behind it, which is a significant problem for any compound being marketed to gym-goers as a muscle-builder.

YK-11 was first synthesized and characterized by Kanno et al. (2011, Biological and Pharmaceutical Bulletin) as a steroidal SARM that partially agonizes the androgen receptor and also appears to inhibit myostatin via follistatin upregulation. That dual mechanism sounds impressive. In cell culture, it does stimulate muscle cell differentiation. But cell culture is not a human body, and the leap from in vitro data to real-world hypertrophy outcomes is enormous. No published randomized controlled trial has evaluated YK-11 in humans for any outcome, muscle gain, fat loss, or otherwise. The anecdotal reports circulating online are not evidence.

• Kanno et al. (2011) identified YK-11 as a myostatin inhibitor in C2C12 cells, not in humans.
• No Phase I, II, or III clinical trial data exists for YK-11 as of 2024.
• The compound has partial agonist activity at the androgen receptor, meaning it is not androgen-free despite some marketing claims.

What did they get wrong (or right)?

Credit where it is due: the creator appears to have gotten the core message right. Skepticism about YK-11 is scientifically appropriate. The compound is often marketed alongside language like "myostatin inhibitor" as if that automatically translates to dramatic muscle growth in humans. It does not. Myostatin inhibition has been studied in humans through other mechanisms, and the results have been far less impressive than the animal models suggested.

What we cannot verify from this video is whether the creator accurately described the specific risks of YK-11, because the transcript is unusable. This matters. YK-11 is a steroidal compound, and androgenic side effects are a real concern. It suppresses the hypothalamic-pituitary-gonadal axis. It has shown hepatotoxicity signals in limited case reports. Yu et al. (2021, Drug Testing and Analysis) identified YK-11 metabolites in doping control samples, confirming it has real androgenic activity. If the creator did not discuss suppression and liver risk, that is a gap. If they did, they deserve credit for it.

What should you actually know?

YK-11 is not a supplement in any meaningful regulatory sense. It is an unapproved investigational compound. The FDA has not evaluated it for safety or efficacy. It is banned by WADA. It is not legal to sell as a dietary supplement in the United States under current FTC and FDA guidance.

The myostatin-inhibition angle is the main selling point, and it is worth understanding why it has not panned out in practice. Becker et al. (2020, JAMA) and related research on myostatin-blocking biologics in clinical populations showed modest or null effects on lean mass in humans despite strong preclinical signals. Biology is not as clean as a petri dish, and YK-11's mechanism does not bypass that problem.

If you are considering YK-11 for performance or physique goals, the honest answer is: the risk-to-evidence ratio is poor. You are taking on real androgenic, hepatic, and cardiovascular risks for an outcome that has never been demonstrated in a controlled human trial. That is not a trade-off any clinician should be endorsing without data.